Listen on the go
CORRECT!
Next question
touchNEUROLOGY touchNEUROLOGY
Movement Disorders

Edwin B George, AAN 2018 – Multiple system atrophy (MSA) management

Copy Link
Published Online: May 9th 2018

Edwin George (Wayne State University, MI) discusses the limitations of current therapeutic options for multiple system atrophy (MSA), and what have been the most promising recent advances toward management of the condition.

Questions

1. What are the limitations of current therapeutic options in MSA? (0:11)
2. What have been the most promising recent advances in the treatment of MSA? (3:15)

Speaker disclosure: Edwin George is a pro bono advisor on Defeat MSA’s scientific and medical board. He also delivers disease awareness talks for Lundbeck Pharmaceuticals.

Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018.

Share this Video
Related Videos In Movement Disorders
Movement Disorders, Neuromuscular Diseases, Paediatric Neurology
Developed by Touch
World Congress on Controversies in Neurology (CONy): Presidential highlights, Amos D. Korczyn
Watch Time: 7 mins

The 17th World Congress on Controversies in Neurology (CONy) took place March 23-25 2023 in Dubrovnik, Croatia. Prof. Amos D. Korczyn, CONy President (University of Tel-Aviv, Tel-Aviv, Israel) joined touchNEUROLOGY to discuss the main aims and focus of the recent CONy meeting, the unique debate presentation style, and the most exciting debates, topics and highlights […]

Movement Disorders, Parkinson's Disease
Francisco Cardoso: International Parkinson and Movement Disorder Society (MDS) – President update
Watch Time: 13 mins

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]

Movement Disorders
Developed by Touch
Donald Gilbert, AAN 2022: Ecopipam investigated for the treatment of children and adolescents with Tourette’s syndrome – Phase 2b results
Watch Time: 5 mins

Ecopipam is an investigational first-in-class drug being evaluated for the treatment of children and adolescents with Tourette’s syndrome. Prof. Donald Gilbert (Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA) discusses the randomised, double-blind, placebo-controlled phase 2b study investigating ecopipam.  The abstract entitled ‘Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, […]

Trending In Movement Disorders:

World Congress on Controversies in Neurology (CONy): Presidential highlights, Amos D. Korczyn
Movement Disorders, Neuromuscular Diseases, Paediatric Neurology
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72